Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study
Brian Lee, Bethania Santos, Heather McArthur, Alexis LeVee, Austin Kordic, Song Zhang, Joshua J Gruber · 2026
Read Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study by Brian Lee, Bethania Santos, Heather McArthur, Alexis LeVee, Austin Kordic, Song Zhang, Joshua J Gruber (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582044.txt.
Description
Brian Lee and co-authors review care in 2026 for small, node-free triple-negative breast cancers, an aggressive type where heavy therapy's role is unsettled. Big multi-drug regimens with immune therapy are standard for larger tumors, but small ones sit in a grey zone. Charts of 215 patients across centers, 154 at stage one and sixty-one at early stage two, anchor the study.
The stage two group had more high-grade tumors and got far more pre-surgery therapy and immune drugs, they report. Yet recurrence and death rates matched the stage one group. Among pre-treated patients, just over half saw the tumor vanish by surgery, alike in both stages. Similar outcomes under heavier care raise the de-escalation question plainly.
Catalog record
| CREATOR | Brian Lee, Bethania Santos, Heather McArthur, Alexis LeVee, Austin Kordic, Song Zhang, Joshua J Gruber |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |